Hyperion Pharma Consultancy


Vlasmeerstraat 90
5261 TC Vught

T: +31 (0) 641221798 
E: info@hyperion-consultancy.nl
W: www.hyperion-consultancy.nl

Geschreven door Wolter de Vries
CDER: Report on Drug Safety Priorities

CDER: Report on Drug Safety Priorities

FDA’s Center for Drug Evaluation and Research (CDER) published a comprehensive Report on the Drug Safety Priorities 2015-2016: Initiatives and Innovation. It highlights the key safety priorities and details FDA’s mission for ensuring drug safety and the protection of public health.


The report further describes a number of programs that help ensure the safety of drug products and reports on key safety milestones achieved over 2015 and to date in 2016.

According to Janet Woodcock, M.D., Director of CDER, the report goes well beyond previously issued safety-related reports and offers a broader picture of FDA’s safety efforts. It takes into account the whole product lifecycle as envisaged by CDER/FDA and gives an insight into how the FDA operates and where emphasis is being laid on.


FDA: Drug Safety Priorities 2015-2016


Hyperion Pharma Consultancy uses cookies to analyze the use of the website. For example, through such statistics, it is examined how often you visit the website of Hyperion Pharma Consultancy. These cookies could also be placed by third parties. By accepting this announcement or continuing to use this site, you agree to this. More information